Protalix BioTherapeutics (PLX) Gross Margin (2010 - 2026)
Protalix BioTherapeutics' quarterly Gross Margin came in at 87.77% in Q1 2026, up 6866.0% year-on-year from 1.26% in Q1 2025, and up 77.8% quarter-over-quarter from 49.36% in Q4 2025.
Protalix BioTherapeutics has reported Gross Margin for 17 years, with the latest figure at 87.77% in Q1 2026.
- For the quarter ending Q1 2026, Gross Margin rose 6866.0% year-over-year to 87.77%; the trailing twelve-month figure through Mar 2026 stood at 69.97% (up 1999.0% YoY), and the FY2025 full-year result was 48.82%, down 564.0% from the prior year.
- Gross Margin for Q1 2026 stood at 87.77%, up from 49.36% in the prior quarter.
- The five-year high for Gross Margin was 87.77% in Q1 2026, with the low at 15.54% in Q4 2023.
- Average Gross Margin over 5 years is 54.19%, with a median of 53.37% recorded in 2024.
- Year-over-year, Gross Margin sank 5664 bps in 2023 and soared 6866 bps in 2026.
- Tracing PLX's Gross Margin over 5 years: stood at 72.18% in 2022, then slumped by 78 bps to 15.54% in 2023, then soared by 406 bps to 78.67% in 2024, then plunged by 37 bps to 49.36% in 2025, then soared by 78 bps to 87.77% in 2026.
- The last three Gross Margin figures came in at 87.77% (Q1 2026), 49.36% (Q4 2025), and 53.37% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 79.04% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 86.85% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 91.79% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 82.22% |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn | 87.77% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 87.77% |
| Dec 31, 2025 | 49.36% |
| Sep 30, 2025 | 53.37% |
| Jun 30, 2025 | 62.51% |
| Mar 31, 2025 | 19.11% |
| Dec 31, 2024 | 78.67% |
| Sep 30, 2024 | 53.37% |
| Jun 30, 2024 | 29.82% |
| Mar 31, 2024 | 30.58% |
| Dec 31, 2023 | 15.54% |
| Sep 30, 2023 | 52.70% |
| Jun 30, 2023 | 82.47% |
| Mar 31, 2023 | 67.82% |
| Dec 31, 2022 | 72.18% |
| Sep 30, 2022 | 50.12% |
| Jun 30, 2022 | 53.31% |
| Mar 31, 2022 | 62.49% |
| Dec 31, 2021 | 63.18% |
| Sep 30, 2021 | 69.28% |
| Jun 30, 2021 | 26.36% |
| Mar 31, 2021 | 57.91% |
| Dec 31, 2020 | 85.88% |
| Sep 30, 2020 | 73.42% |
| Jun 30, 2020 | 83.34% |
| Mar 31, 2020 | 84.17% |
| Dec 31, 2019 | 78.90% |
| Sep 30, 2019 | 77.51% |
| Jun 30, 2019 | 77.99% |
| Mar 31, 2019 | 80.41% |
| Dec 31, 2018 | -29.73% |
| Sep 30, 2018 | -189.14% |
| Jun 30, 2018 | -8.82% |
| Mar 31, 2018 | 35.78% |
| Dec 31, 2017 | 50.83% |
| Sep 30, 2017 | 19.40% |
| Jun 30, 2017 | 13.13% |
| Mar 31, 2017 | 48.66% |
| Dec 31, 2016 | 6.20% |
| Sep 30, 2016 | 9.04% |
| Jun 30, 2016 | 5.31% |
| Mar 31, 2016 | 22.97% |
| Sep 30, 2015 | 83.31% |
| Jun 30, 2015 | 83.16% |
| Mar 31, 2015 | 83.33% |
| Mar 31, 2014 | 49.43% |
| Dec 31, 2013 | 80.27% |
| Sep 30, 2013 | 77.58% |
| Jun 30, 2013 | 77.12% |
| Mar 31, 2013 | 84.00% |
| Dec 31, 2012 | -96.42% |
| Sep 30, 2012 | 81.18% |
| Jun 30, 2012 | 84.17% |
| Mar 31, 2012 | 62.37% |
| Dec 31, 2011 | 12.45% |
| Sep 30, 2011 | 59.81% |
| Jun 30, 2011 | -621.73% |
| Mar 31, 2011 | 126.50% |
| Dec 31, 2010 | 279.08% |
| Sep 30, 2010 | 66.55% |
| Jun 30, 2010 | 53.72% |